SCHEMBL7920120

SCHEMBL7920120

N#CCc1ccc(N2CCCCC2)cc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSC P53634 1/20 0.43
SMN1; SMN2 Q16637 4/20 0.41
KDM4E B2RXH2 2/20 0.41
LMNA P02545 4/20 0.39
MAPT P10636 3/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
ALDH1A1 P00352 3/20 0.39
S100B P04271 2/20 0.39
TERT O14746 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
GAA P10253 1/20 0.39
PKM P14618 1/20 0.39
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PRMT6 Q96LA8 1/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL194982 0.88 LMNA (0.39) CTSCSMN1; SMN2KDM4ELMNAMAPT
SCHEMBL7913817 0.81 L3MBTL1 (0.45) SMN1; SMN2KDM4ELMNAMAPTMEN1
SCHEMBL7907757 0.79 KDM4E (0.44) CTSCSMN1; SMN2KDM4ELMNAMAPT
SCHEMBL7913786 0.78 ALDH1A1 (0.39) SMN1; SMN2KDM4ELMNAMAPTMEN1
SCHEMBL21737191 0.77 MAPT (0.45) SMN1; SMN2KDM4EMAPTMEN1KMT2A
SCHEMBL10237121 0.76 ALDH1A1 (0.41) SMN1; SMN2LMNAMAPTALDH1A1GAA
SCHEMBL22242861 0.76 SMN1; SMN2 (0.41) SMN1; SMN2KDM4ELMNAMAPTMEN1
SCHEMBL142269 0.76 CYP11B1 (0.50) SMN1; SMN2KDM4ELMNAMAPTMEN1
SCHEMBL15976200 0.76 CYP11B1 (0.50) SMN1; SMN2KDM4ELMNAMAPTMEN1
SCHEMBL7916967 0.75 SLC16A3 (0.50) KDM4ELMNAMAPTALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8754100-B2 Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors EISAI R&D MANAGEMENT CO., LTD. (JP) 2014-06-17 US disclosed
US-8754100-B2 Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors EISAI R&D MANAGEMENT CO., LTD. (JP) 2014-06-17 US disclosed
EP-2401276-B1 NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS EISAI R&D MAN CO LTD (JP) 2013-06-05 EP disclosed
US-20120053171-A1 Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors EISAI R&D MANAGEMENT CO., LTD., (JP) 2012-03-01 US disclosed
US-20120053171-A1 Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors EISAI R&D MANAGEMENT CO., LTD., (JP) 2012-03-01 US disclosed
WO-2010098487-A1 NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053171-A1 Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors BACE1, APP, PSEN1 CTSC 1147/4885SMN1; SMN2 357/4885KDM4E 3198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.